Drug Trial Radar · NCT02371369
Phase 3 Study of Pexidartinib for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS)
Last checked: Nov 20, 2026Latest source record: May 11, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
120
Actual
Start
May 11, 2015
Primary completion
Mar 27, 2017
Study completion Apr 30, 2021
Sponsor
- Lead sponsor
- Daiichi SankyoDaiichi Sankyo (DSNKY)
- Sponsor type
- Industry
- First posted
- Feb 25, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3 clinical study, which aims to evaluate the effectiveness of an investigational drug called pexidartinib for the treatment of certain tumors for which surgical removal could cause more harm than good. The main purpose of this study is to gather information about the investigational drug pexidartinib, which may help to treat tumors of pigmented villonodular synovitis (PVNS) or giant cell tumor of the tendon sheath (GCT-TS). The study consists of two parts with a follow-up period. In Part 1, eligible study participants will be assigned to receive either pexidartinib or matching placebo for 24 weeks. A number of assessments will be carried out during the course of the study, including physical examinations, blood tests, imaging studies, electrocardiograms, and questionnaires. MRI scans will be used to evaluate the response of the tumors to the treatment. Some subjects, assigned to placebo in Part 1 transitioned to pexidartinib for Part 2. Then a protocol amendment was written to allow only pexidartinib patients to continue into Part 2. Part 2 is a long-term treatment phase in which all participants receive open-label pexidartinib. There was also a follow-up period added to Part 2.
Conditions
- Pigmented Villonodular Synovitis
- Giant Cell Tumors of the Tendon Sheath
- Tenosynovial Giant Cell Tumor
Interventions
PexidartinibDrug
Each capsule contains 200 mg of pexidartinib for oral administration
PlaceboDrug
Placebo capsule matching pexidartinib capsule for oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Symptomatic, Locally Advanced Tenosynovial Giant Cell Tumor (TGCT) Achieving Complete or Partial Response to Pexidartinib Compared With That of Placebo Per Response Evaluation Criteria in Solid Tumors Version 1.1 at Week 25Time frame: Week 25
Locations
39 sites in 12 countries. Site status is shown where the registry gives one.
Mayo Clinic
Scottsdale, Arizona
University of Southern California
Los Angeles, California
Stanford Cancer Center
Palo Alto, California
UCLA Medical Center
Santa Monica, California
Mayo Clinic Cancer Center
Jacksonville, Florida
Sylvester Comprehensive Cancer Center
Miami, Florida
Moffitt Cancer Center
Tampa, Florida
Massachusetts General Hospital
Boston, Massachusetts
: Dana Farber Cancer Institute
Boston, Massachusetts
Michigan Comprehensive Cancer Center
Ann Arbor, Michigan
Mayo Clinic Cancer Center
Rochester, Minnesota
Washington University School of Medicine
St Louis, Missouri
MD Anderson Cancer Center at Cooper
Camden, New Jersey
Memorial Sloan Kettering Cancer Center
New York, New York
Duke Cancer Center
Durham, North Carolina
OHSU Knight Cancer Institute
Portland, Oregon
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee
Huntsman Cancer Institute
Salt Lake City, Utah
Seattle Cancer Care Alliance
Seattle, Washington
Chris O'Brien Lifehouse
Sydney, New South Wales, Australia
Princess Alexandra Hospital
Woolloongabba, Queensland, Australia
Peter MacCallum Cancer Centre
East Melbourne, Victoria, Australia
Princess Margaret Hospital
Toronto, Ontario, Canada
McGill University Health Centre
Montreal, Quebec, Canada
Herlev Hospital
Herlev, Denmark
Centre Leon Bérard
Lyon, France
Institut Gustave Roussy
Villejuif, France
HELIOS Klinikum Berlin-Buch
Berlin, Germany
Universitätsklinikum Essen
Essen, Germany
Military Hospital-State Health Center
Budapest, Hungary
Istituto Ortopedico Rizzoli
Bologna, BO, Italy
Istituto Nazionale Tumori-Fondazione IRCCS
Milan, MI, Italy
Leiden University Medical Center
Leiden, Netherlands
Radboud Univ. Medical Center
Nijmegen, Netherlands
Centrum Onkologii-Instytut im. Marii Skłodowskiej-Curie
Warsaw, Poland
Hospital de la Santa Creu i Sant Pau
Barcelona, Spain
Hospital Universitario Virgen del Rocío
Seville, Spain
University College Hospital
London, United Kingdom
The Royal Marsden NHS Foundation Trust
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.